Pivot Pharma Launches Cannabis and Nutraceutical Facility in Quebec

cannabis

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) has launched its cannabis and nutraceutical manufacturing facility in Dollard-des-Ormeaux, Quebec, Canada.

Story continues below

The facility, along with R&D and pilot-scale laboratories, is comprised of 43 000 square feet of production and packaging space designed to optimize the manufacturing processes of Pivot branded value-added CBD and nutraceutical consumer products.

The company plans to start the production activities in the next three months, pending the Health Canada license reception.

Pivot is nearing the completion of its state-of-the-art building and is preparing the submission of its site evidence package to Health Canada, the final step toward securing the Health Canada license. The infrastructure will be used to develop novel formulations and production of Pivot’s CBD, phytocannabinoid and micronutrient product lines using Pivot’s patented and drug delivery technologies.

“This facility will enable us to launch our product pipeline in the Canadian market and thus further consolidating Pivot’s strategic positioning with ramping sales of specialty CBD products and micronutrient formulations in Germany and planed product launches in the U.S. marketplace in Q1 2020,” Pivot CEO Dr. Toni Rinow stated.

An ad to help with our costs